JASUBHAI GROUP      ABOUT CHEMTECH     ADVISORY BOARD     AWARDS       EVENTS     PUBLICATIONS     CONTACTUS    
Chemical & Processing
EPC
Oil & Gas
Refining
Automation
Pharma Biotech
Shipping
Power
Water
Infrastructure & Design

Coded Holograms to Keep the Supply Chain Secure
Everyone involved in the goods supply chain has learnt the value of security holograms and will be reassured by their presence on products and/or the packaging, due to the benefits they provide. As coding and serialisation become mandated in various countries for products like medicines, the ability to incorporate different types of codes into holograms further enhances the role they can play in supply chain control says Ian Lancaster, General Secretary, International Hologram Manufacturers Association in an interview to Pharma Bio World.
Ian Lancaster, General Secretary,
International Hologram Manufacturers Association
Innovation has been the mainstay of the company
Dr Villoo Morawala Patell, Chairman and Managing Director, Avesthagen in an interview with Ananya Sen discusses Avesthagen’s spine: “innovation”
Dr Villoo Morawala Patell
Chairman and Managing Director, Avesthagen
The rules for clinical trials in other countries are easy to comply with in comparison with India
Venus Remedies has been exploring several international markets and recently made news on acquiring marketing approval for meropenem in Italy. Pawan Chaudhary, Chairman and Managing Director, Venus Remedies in an interview with Ananya Sen discusses more on this.
Pawan Chaudhary,
Chairman and Managing Director, Venus Remedies
Our mission has been to offer even our innovative molecules at an affordable price.
Mycidac-C is priced at about a tenth of the cost of those made by multinational competitors. Dr Rajiv Modi, CMD, Cadila Pharmaceuticals in an interview with Ananya Sen discusses Cadila’s innovation Mycidiac-C and their new research partnership.
Dr Rajiv Modi,
CMD, Cadila Pharmaceuticals
Access to Medicine: Moral Imperative and a New Consciousness
This series of five articles will address the main issues of the seemingly unending debate, beginning with an introduction of the key concepts and the international agreements that establish, or seek to establish, access to medicine as a human right, and, in the last article, offering a way forward.
Jenik Radon,
Adjunct Professor of Columbia School of International and Public Affairs
Need for a Smarter Regulatory System to Ensure Access to Affordable Biologics: The Biosimilars
The use of biologics is fast gaining traction around the globe because they can address medical needs that conventional therapeutics cannot, including many cancers, immunological and genetic diseases. Unfortunately, the development of biologics is hugely expensive and the high cost factor makes them inaccessible to a larger patient population.
- Kiran Mazumdar Shaw
CMD, Biocon
Aftermath of the Drug Price Control Order 2013
The Drugs (Prices Control) Order, 2013 announced on 15th May 2013 by the Department of Pharmaceuticals, in an attempt to avail drugs at an affordable price to the Indian population has created a stir in the Pharma Industry.
- Dr Gopakumar Nair
Founder, Gopakumar Nair Associates
Extending Provision of Compulsory Licensing
Compulsory Licensing is intended not to deprive the innovator companies from earning due income but only discourage them from enjoying monopolistic profits.
- Saurabh Chandra
Secretary, DIPP
NGS is a Natural Evolution from Early Methods
Perhaps the timely analysis of the vast amounts of data from NGS instruments is the biggest and most significant hurdle we have to face to make an impact on cancer care.
– Dr Elaine Mardis
Moving up the Value Chain - The Biocon Way!
Biocon's business model reflects company's strategic move up the value chain, and the company plans to leverage its five business verticals and touch USD 1 billion by 2018.
Kiran Mazumdar Shaw
Founder and CMD, Biocon
Pages » 1 2 3